Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of NET Power, Inc. regarding a class action lawsuit due to allegations of misleading statements and failure to disclose critical information related to Project Permian [1]. Group 1: Allegations - The complaint alleges that NET Power was unlikely to complete its first utility-scale plant, Project Permian, on schedule and that the project would be significantly more expensive than previously represented due to supply chain issues and site-specific challenges [1]. - Defendants' projections regarding the time and capital needed to complete Project Permian were deemed unrealistic [1]. - The increased time and capital requirements for Project Permian are likely to negatively impact the company's business and financial results [1]. - Public statements made by the defendants were materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is from June 9, 2023, to March 7, 2025 [1]. - Shareholders are encouraged to register for the class action by June 17, 2025, to potentially be appointed as lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Company Overview - Cable One, Inc. is a broadband communications provider offering high-speed internet, video, and voice services through its brands, including Sparklight, Fidelity, Hargray, and CableAmerica [3] Allegations and Financial Performance - On May 1, 2025, Cable One reported first-quarter earnings that significantly fell short of analyst expectations and announced plans to suspend its anticipated dividend [4] - Analysts from KeyBanc and Raymond James raised concerns about the company's credibility, noting that the results contradicted prior management statements forecasting growth in subscribers and broadband revenue [4] Market Reaction - Following the earnings report, Cable One's stock price dropped by $109.48 per share, or 41.79%, closing at $152.51 per share on May 2, 2025 [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and operational funding [3][5]. Group 1: Legal Investigation - The firm is reminding investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Zenas [3]. - The complaint alleges that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [5]. Group 2: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Zenas' conduct [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of violations of federal securities laws related to misleading statements and undisclosed costs impacting financial results [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Canopy Growth, with a deadline of June 3, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses from Canopy Growth between May 30, 2024, and February 6, 2025, are encouraged to discuss their legal options with Faruqi & Faruqi [1][3]. Group 2: Financial Performance and Allegations - The complaint alleges that Canopy Growth and its executives made false or misleading statements regarding the company's financial health, particularly concerning the costs associated with the Claybourne product launch and Storz & Bickel vaporizer devices [5]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs related to the Claybourne product launch and increased indirect costs [6]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [6]. Group 3: Market Reaction - Following the announcement of its financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [8].

Core Viewpoint - ADTRAN Holdings, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following the disclosure of issues with its financial statements [1][2]. Financial Disclosure - On May 13, 2025, ADTRAN announced that its audited consolidated financial statements for the years ended December 31, 2024, and December 31, 2023, as well as its unaudited condensed financial statements for interim periods in 2024, should no longer be relied upon and would be restated [2]. - The company identified at least one additional material weakness in its internal control over financial reporting as of December 31, 2024 [2]. - Following this announcement, ADTRAN's stock price decreased by $0.41, or 4.79%, closing at $8.15 per share on May 14, 2025 [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ADTRAN stockholders who may have suffered losses due to the company's financial disclosures [1][3].

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Compass owns ...

Core Insights - Iovance Biotherapeutics is under investigation for potential violations of federal securities laws and unlawful business practices [1] - The company reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million, down from $73.7 million in the previous quarter [3] - Iovance has revised its full fiscal year 2025 revenue guidance from a range of $450 million-$475 million to $250 million-$300 million, representing a reduction of over 40% at the midpoint [3] - Following the announcement, Iovance's share price dropped by $1.42, or approximately 44%, closing at $1.75 on May 9, 2025 [3] Company Performance - The first quarter 2025 product revenue of $49.3 million indicates a significant decrease compared to the previous quarter's revenue of $73.7 million [3] - The revision of the full-year 2025 revenue guidance reflects challenges in the launch dynamics of the T cell immunotherapy, Amtagvi (lifileucel), which was launched in the U.S. in the first half of 2024 [3] Market Reaction - The announcement of the revenue decline and guidance revision led to a sharp decline in Iovance's stock price, falling from $3.17 to $1.75 within a day [3]

Core Viewpoint - Cleveland-Cliffs Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results and operational changes [1][3]. Financial Performance - Cleveland-Cliffs reported a larger than expected adjusted loss for Q1 2025, with a year-over-year revenue decline of 11% to $4.63 billion [3]. - The company's share price fell from $8.49 on May 7, 2025, to $7.15 on May 8, 2025, a decline of $1.34 per share [3]. Operational Changes - The company plans to fully or partially idle six steel plants due to negative impacts from underperforming non-core assets and lower index prices from late 2024 and early 2025 [3]. - Cleveland-Cliffs is repositioning its portfolio away from non-core markets, including rail, high-carbon sheet, and specialty plate products, and is focusing on the automotive industry [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased Zenas BioPharma securities during the specified class period [3]. - Allegations include that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [6]. - The firm seeks recovery for investors who suffered losses due to misleading statements that artificially inflated the company's stock [6].

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE:CODI). The investigation concerns whether Compass and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 7, 2025, after the markets closed, Compass filed a Form 8-K which stated that the Audit Committee of Board ...